IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces that a class action lawsuit has been filed against GW Pharmaceuticals plc (“GW Pharmaceuticals” or the “Company”) (Nasdaq: GWPH). Investors who purchased or otherwise acquired shares between December 4, 2014 and January 8, 2016, inclusive (the “Class Period”) are encouraged to contact the Firm prior to the March 21, 2016, lead plaintiff motion deadline.
If you purchased shares of GW Pharmaceuticals during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by email at firstname.lastname@example.org.
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
According to the complaint, the Company made false and/or misleading statements and/or failed to disclose that: (1) GW Pharmaceuticals lacked effective internal financial controls; and (2) GW Pharmaceuticals lacked effective controls over completeness and valuation of clinical trial accruals.
If you purchased shares of GW Pharmaceuticals during the Class Period, you have until March 21, 2016 to ask the Court to appoint you as lead plaintiff. If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by email at email@example.com.
This press release may constitute Attorney Advertising in some jurisdictions.